MonoGen Announces First MonoPrep Customer Order

LINCOLNSHIRE, ILLINOIS--(Marketwire - June 19, 2008) - MonoGen, Inc. (TSX:MOG)(the "Corporation") today announced that it has received its first customer purchase order for its flagship product, the MonoPrep Processor.

"We are extremely pleased to announce this significant milestone for MonoGen," said Jim Cureton, MonoGen's Vice President of Sales and Marketing. "Our direct sales force calling on laboratories has generated significant interest in MonoPrep and we are encouraged by the positive response the sales team has received from our customers. It's clear that the market sees the advantages of MonoPrep's unique design and the improvements it brings to their current cytology operations. We look forward to many more successes over the coming months as we ramp-up our commercial launch activities."

About MonoGen, Inc.

MonoGen, Inc., headquartered in the Chicago area, is a medical device and diagnostics company providing high-quality and cost-effective cytological screening and diagnostic products to healthcare providers in the anatomic pathology industry.

Forward-Looking Statements

This press release contains forward-looking statements. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements. Forward-looking statements are based on our beliefs and assumptions based on information available at the time the assumptions were made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause our actual results to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to, our ability to raise additional capital, our ability to execute our business plan while maintaining at all times our various regulatory approvals, and the response from existing and potential competitors. Additional discussions of the various risks are contained in our Annual Information Form dated March 19, 2008, which is available on SEDAR (www.sedar.com). Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document.